Dataset Information

Associations of Childhood Maltreatment With Suicidal Behavior Among Chinese Adolescents: Does It Differ Based on Gender and Biological Rhythm?

ABSTRACT:

Background

The impact of biological rhythm disorder (BRD) on the association of childhood maltreatment (CM) and suicidal behavior in adolescents remains unclear. CM increases the risk of suicidal ideation (SI), suicidal planning (SP), and suicidal attempts (SAs). There is less investigation on gender differences in CM's effects on suicidal behavior. It is unknown whether the impacts vary with different levels of BRD.

Aims

To identify gender differences in CM's effects on suicidal behavior and to investigate these impacts at different levels of BRD.

Method

The analysis is based on data from 7,986 adolescents recruited from three cities in China between October and December 2019. All participants, aged 14.7 ± 2 years, filled out standard questionnaires involving CM, BRD, and suicidal behavior.

Results

A total of 22.9, 10.8, and 4.7% of the adolescents reported SI/SP/SAs in the past year. Girls are more likely to engage in SI and SP when exposed to the highest level of CM; boys are more likely to engage in SAs than girls. A significant relationship between moderate levels of CM and SI/SP/SAs was only observed in girls exposed to low BRD. Moderate CM is only significantly associated with SI in boys exposed to low BRD. The percentage of low-BRD adolescents who experienced high CM was 31.4%, whereas 58% of high-BRD adolescents experienced high CM in SI. Adolescents with high BRD were more likely to experience high levels of CM in SP and SAs.

Conclusions

Adolescents at high risk of suicidal behavior in relation to CM should be targeted accordingly. Improving biological rhythm in adolescents who experience CM could help prevent them from engaging in suicidal behavior.

SUBMITTER: Xie Y

PROVIDER: S-EPMC9309254 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundChildhood maltreatment is one of the strongest predictors of adulthood depression and alterations to circulating levels of inflammatory markers is one putative mechanism mediating risk or resilience.AimsTo determine the effects of childhood maltreatment on circulating levels of 41 inflammatory markers in healthy individuals and those with a major depressive disorder (MDD) diagnosis.MethodWe investigated the association of childhood maltreatment with levels of 41 inflammatory markers in two groups, 164 patients with MDD and 301 controls, using multiplex electrochemiluminescence methods applied to blood serum.ResultsChildhood maltreatment was not associated with altered inflammatory markers in either group after multiple testing correction. Body mass index (BMI) exerted strong effects on interleukin-6 and C-reactive protein levels in those with MDD.ConclusionsChildhood maltreatment did not exert effects on inflammatory marker levels in either the participants with MDD or the control group in our study. Our results instead highlight the more pertinent influence of BMI.Declaration of interestD.A.C. and H.W. work for Eli Lilly Inc. R.N. has received speaker fees from Sunovion, Jansen and Lundbeck. G.B. has received consultancy fees and funding from Eli Lilly. R.H.M.-W. has received consultancy fees or has a financial relationship with AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Ferrer, Janssen-Cilag, Lundbeck, MyTomorrows, Otsuka, Pfizer, Pulse, Roche, Servier, SPIMACO and Sunovian. I.M.A. has received consultancy fees or has a financial relationship with Alkermes, Lundbeck, Lundbeck/Otsuka, and Servier. S.W. has sat on an advisory board for Sunovion, Allergan and has received speaker fees from Astra Zeneca. A.H.Y. has received honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen. A.J.C. has received honoraria for speaking from Astra Zeneca, honoraria for consulting with Allergan, Livanova and Lundbeck and research grant support from Lundbeck.